176 related articles for article (PubMed ID: 38124732)
1. Novel heterozygous
Rossano M; Conti EA; Bocca P; Volpi S; Mastrangelo A; Cavalli R; Gattorno M; Minoia F; Filocamo G
Front Immunol; 2023; 14():1288675. PubMed ID: 38124732
[TBL] [Abstract][Full Text] [Related]
2. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity.
Gallucci S; Meka S; Gamero AM
Cytokine; 2021 Oct; 146():155633. PubMed ID: 34340046
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus overlapping dermatomyositis owing to a heterozygous TREX1 Asp130Asn missense mutation.
Endo Y; Koga T; Otaki H; Furukawa K; Kawakami A
Clin Immunol; 2021 Jun; 227():108732. PubMed ID: 33892200
[TBL] [Abstract][Full Text] [Related]
5. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
6. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.
Namjou B; Kothari PH; Kelly JA; Glenn SB; Ojwang JO; Adler A; Alarcón-Riquelme ME; Gallant CJ; Boackle SA; Criswell LA; Kimberly RP; Brown E; Edberg J; Stevens AM; Jacob CO; Tsao BP; Gilkeson GS; Kamen DL; Merrill JT; Petri M; Goldman RR; Vila LM; Anaya JM; Niewold TB; Martin J; Pons-Estel BA; Sabio JM; Callejas JL; Vyse TJ; Bae SC; Perrino FW; Freedman BI; Scofield RH; Moser KL; Gaffney PM; James JA; Langefeld CD; Kaufman KM; Harley JB; Atkinson JP
Genes Immun; 2011 Jun; 12(4):270-9. PubMed ID: 21270825
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
9. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
10. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
Chyuan IT; Tzeng HT; Chen JY
Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X
Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618
[TBL] [Abstract][Full Text] [Related]
12. Familial chilblain lupus due to a gain-of-function mutation in STING.
König N; Fiehn C; Wolf C; Schuster M; Cura Costa E; Tüngler V; Alvarez HA; Chara O; Engel K; Goldbach-Mansky R; Günther C; Lee-Kirsch MA
Ann Rheum Dis; 2017 Feb; 76(2):468-472. PubMed ID: 27566796
[TBL] [Abstract][Full Text] [Related]
13. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.
Ikeda K; Hayakawa K; Fujishiro M; Kawasaki M; Hirai T; Tsushima H; Miyashita T; Suzuki S; Morimoto S; Tamura N; Takamori K; Ogawa H; Sekigawa I
BMC Immunol; 2017 Aug; 18(1):41. PubMed ID: 28830352
[TBL] [Abstract][Full Text] [Related]
14. Typing TREX1 gene in patients with systemic lupus erythematosus.
Fredi M; Bianchi M; Andreoli L; Greco G; Olivieri I; Orcesi S; Fazzi E; Cereda C; Tincani A
Reumatismo; 2015 Jun; 67(1):1-7. PubMed ID: 26150267
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.
Ll Wilkinson MG; Deakin CT; Papadopoulou C; Eleftheriou D; Wedderburn LR
Pediatr Rheumatol Online J; 2021 Sep; 19(1):146. PubMed ID: 34563217
[TBL] [Abstract][Full Text] [Related]
16. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus.
Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2022 Mar; 18(3):245-252. PubMed ID: 35138987
[TBL] [Abstract][Full Text] [Related]
17. Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib.
Zhang S; Song J; Yang Y; Miao H; Yang L; Liu Y; Zhang X; Liu Y; Wang T
Pediatr Rheumatol Online J; 2021 Jan; 19(1):1. PubMed ID: 33407657
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition.
Nikolopoulos D; Parodis I
Front Med (Lausanne); 2023; 10():1217147. PubMed ID: 37457579
[TBL] [Abstract][Full Text] [Related]
20. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease.
Kuriyama Y; Shimizu A; Kanai S; Oikawa D; Motegi SI; Tokunaga F; Ishikawa O
Sci Rep; 2021 Nov; 11(1):23146. PubMed ID: 34848794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
